Indian pharma companies forecast 30% growth in 2017 at CPHI India
Domestic sales identified as chief driver behind unexpected rise in revenues.
CPHI and P-MEC India, part of India Pharma Week – organised by UBM EMEA and UBM India – closed yesterday as in-depth research from over 400 Indian pharma companies forecast rapid growth for the Indian pharma economy in 2017. Chief amongst the growth drivers reported are strong domestic sales in the next 2-3 years, generic APIs exports, as well as finished formulation for developed markets.
The findings show that industry confidence is now extremely high, with domestic manufacturers bullish about near-term revenue prospects, averaging a predicted 30.5% growth in 2017. An analysis by sector shows that, of the 400 companies, 60% believed that finished formulations would expand rapidly, while 42% see APIs as the largest growth area. Highlighting the economy’s diversity and willingness to incorporate new product classes, 25% of respondents regard biosimilars and biologics as a burgeoning sector in 2017, particularly following the updated CDSCO biosimilars guidelines.
Indian pharma has benefited from an exponential growth rate in the past decade, yet this has cooled in recent years while the industry invested in new infrastructure and improving regulatory standards. However, this new data points to a renewed confidence that will drive another period of strong growth in Indian pharma.
These findings are announced as over 40,000 attendees visit Mumbai for the special 10-year anniversary of CPHI and P-MEC India, including India Pharma week. Over the past 7 days, the event helped stimulate this predicted growth as it brought together buyers from Germany, China, Italy, Japan and the United States, along with Indian pharma companies for commercial discussions, knowledge sharing and analysis.
One of the underlying reasons behind the renewed confidence in the market is the improving quality standards, as 67% of respondents stated they expected to meet the approaching CDSCO certification deadline on 1 January 2018.
In the past 10 years the industry has largely expanded its dollar value through international exports. This is set to continue as a major growth factor in the near future, with more USFDA approvals in the last year (201 ANDA up from 109) paving the way for increased generics sales in the United States. However, not only are exports increasing, but also, the gentrification of the Indian healthcare economy is leading to an unprecedented surge in demand for domestic pharma. An impressive 70% of respondents anticipate domestic sales will be the main driver of growth for Indian pharma in the next 3-5 years.
One of the companies surveyed, commented: “India is seeing great opportunities in a variety of areas - we are seeing strong growth in exports to developed markets, and strong development domestically. Our pharma companies are on par with US and European standards, so we foresee more high value Indian export to developed countries at a lower rate. Domestically, more and more Indian people now have health insurance, and consumer spending is increasing as areas start urbanising rapidly, so we are also experience high levels of demand across the country, helping drive our domestic sales.”
Indian Pharma Week featured 10 tailored events including the leading Pre-Connect congress, the UBM India Pharma Awards, Pharma Leaders golf, CEO roundtables, alongside the CPHI and P-MEC India exhibition, bringing together over 1,200 exhibitors. Taking place in two separate venues - the Bombay Exhibition Centre and the BKC - the exhibition connected attendees with pharma and generics companies, ingredients manufacturers, pharma machinery, packaging experts, CDMOs, CROs, biotech and biosimilar companies.
Rutger Oudejans, Brand Director Pharma at UBM EMEA, said: “India’s domestic market is showing extreme confidence amongst its domestic manufacturing base. The government is actively supporting the pharma industry through several initiatives such as dedicated pharma parks, boosting the biosimilars and biologics sector, and reducing manufacturing costs.
"Our role at UBM is to facilitate these growth drivers, cultivate innovation and promote networking within the pharma industry. A key element for us is to help pharma executives make better-informed decisions and so create bigger business opportunities.
"The future looks very promising for Indian manufacturing as we are seeing greater confidence along the entire supply chain, particularly across the P-MEC customer base. Machinery is playing a key role in the development of the industry as it supplies the necessary infrastructure to sustain India’s growth for the next 5 years.
"After 10 years of CPHI India, we should reflect on what the industry has achieved. India has succeeded by seeking innovative ideas and setting new limits, reimagining what is possible and lowering costs. In the next 10 years India could see even more startling and bold innovation, as our survey findings indicate Indian pharma is set to accelerate its development, and grow ahead of analyst projections.”
Related News
-
News A Day in the Life of a Pharma Event Director
The Day in the Life of series has covered most of the pharmaceutical supply chain looking through the eyes of the people working in the different fields, from R&D to manufacturing. What we haven't seen yet, is the role that non-pharma companies can... -
News On Track at CPHI Milan: The RTU Alliance on the importance of packaging innovation
As CPHI Milan gets ever closer, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma, and the innovations that are set to shake up the industry. -
News CPHI Milan Speaker Spotlight: The microbiome and investing in future therapies
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conference. -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News Latest updates for semaglutide: reduction of renal failure risk
Recent data presented at the 2024 European Society for Cardiology (ESC) conference analysed Novo Nordisk’s Ozempic (semaglutide) and its effectiveness in the management of chronic kidney disease (CKD). This follows previous analysis on semaglutid... -
News CPHI Milan Speaker Spotlight: CDMO relations with Pharma and Start-Ups
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News What can you expect from CPHI Milan 2024?
CPHI Milan 2024 marks the 35th anniversary of CPHI. The 35th Edition of the show, taking place 8–10 October, promises to be a celebration of everything pharma, covering every sector, and featuring thought leaders and trailblazers shaking up the i...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance